Company Research Highlights® Report (PDF)
VARIOUS THIRD PARTIES - 11/04/13
This generated report* compiles independent, third-party information highlighting key fundamental and technical data, analyst opinions, stock price movement, earnings data, and industry comparisons. Available only to Fidelity customers.
S&P Capital IQ Company Report
S&P Capital IQ - 11/04/13
This generated report* has historical data on financials with interactive charts, technical indicators, and five-year peer comparison trend charts.
RELISTOR is indicated for the treatment of opioid-induced constipation in patients with advanced illness who are receiving palliative care, when response to laxative therapy has not been sufficient. Use of RELISTOR beyond four months has not been studied.
Q2 2013 from Salix Pharmaceuticals Q2 Report: "48% Increase in Year-over-Year 2Q RELISTOR® Prescriptions"
Could be forming a bottoming candlestick, too early to say. Looking for long tail with a head on top.